Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Antihyperglycemic Medications · 1 trial · 1 indication
Hemoglobin A1c (HbA1c) is a test that measures a participant's average blood glucose level over the past 2 to 3 months. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis adjusting for treatment, stratification factors (region, sulfonylureas/meglitinide use, baseline Low-Density Lipoprotein \[LDL-C\], visit, treatment-by-visit interaction, and baseline HbA1c as fixed effects and participants as the random effect. P-value is from MMRM with terms for treatment, visit, treatment-by-visit interaction, stratification, and baseline HbA1C.
| Arm | Type | Description |
|---|---|---|
| Insulin Peglispro | EXPERIMENTAL | Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs). |
| Insulin Glargine | ACTIVE_COMPARATOR | Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs. |
| Name | Type | Description |
|---|---|---|
| Insulin Peglispro | DRUG | Administered SC using a prefilled pen. |
| Insulin Glargine | DRUG | Administered SC using a prefilled pen |
| Oral Antihyperglycemic Medications (OAMs) | DRUG | Administered orally |
Inclusion Criteria: * Have Type 2 Diabetes Mellitus (T2DM) for at least 1 year not treated with insulin * Have been receiving at least two oral antihyperglycemic medications (OAMs) for at least 3 months prior to screening * Have Hemoglobin A1c (HbA1c) of 7.0% to 11.0%, inclusive, according to centr...
Antihyperglycemic Medications is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 3 clinical development, meaning it has not yet been approved and is still being studied to determine its safety and effectiveness in patients.
Antihyperglycemic Medications is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate this investigational drug for the treatment of Type 2 Diabetes Mellitus.
Antihyperglycemic Medications is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 3 trial for this drug has been completed, and it is being studied for the treatment of Type 2 Diabetes Mellitus.
Antihyperglycemic Medications has one completed Phase 3 clinical trial with the identifier NCT01894568. The trial, titled 'A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment,' enrolled 388 participants with Type 2 Diabetes Mellitus in Japan, South Korea, and Taiwan.
Antihyperglycemic Medications is the drug being studied in a clinical trial that compares Insulin Peglispro with Insulin Glargine. The trial is evaluating these treatments as basal insulin therapy for Type 2 Diabetes Mellitus, but the drug name Antihyperglycemic Medications refers to the class of medications being investigated.